Stockreport

Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF GLUE's pipeline features MRT-6160 (VAV1 degrader, partnered with Novartis), MRT-8102 (NEK7 degrader), and MRT-2359 (oncology), offering both I&I and oncology upside. [Read more]